PHARMACOKINETICS & SAFETY OF SUSTAINED-RELEASE FLUCYTOSINE PELLET FORMULATION
Background: WHO recommends flucytosine (5FC) as an essential component of cryptococcal meningitis (CM) treatment regimens. The currently available formulation, an immediate release (IR) tablet, needs to be administered four times a day and is sub optimal for administration via naso-gastric tube. This study evaluated the pharmacokinetics and safety of a sustained release 5FC (SR) pellet…